Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

Wolfe Research: 'VERA's continued weakness is creating a favorable setup into the July 7th PDUFA'

June 2, 2026 12:28 PM EDT

Wolfe Research analyst Andy Chen reiterated an Outperform rating and $88.00 price target on Vera Therapeutics (NASDAQ: VERA)

The analyst comments "Fundamentally positive Vera for a few reasons (i) normally, Vera would need 96- week eGFR stabilization data to achieve full approval. In our view, this lowers the risk of eGFR failure, precluding the... More